Combined AXL inhibition and PD-1 blockade was shown to mount a potent synergistic antitumor efficacy, leading to tumor eradication in ovarian cancer murine models by inducing the expression of T cell-recruiting chemokines (e.g., CXCL9, CXCL10, and CXCL11), while decreasing the expression of chemokines related to suppressive cell recruitment (e.g., CCL2, CCL3, and CCL4). The gene discussed is AXL; the disease is neoplasm.